MicroStockProfit.com releases investment report on Somanetics

MicroStockProfit.com announces an investment report featuring Somanetics Corp. (Nasdaq:SMTS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/SMTS

Somanetics Corp. (SMTS) develops, manufactures and markets the INVOS System, a non-invasive patient monitoring system that provides accurate, real-time blood oxygen measurements in the brain and elsewhere in the body in tissues beneath the sensor in patients greater than 2.5 kilograms and continuously measures changes in blood oxygen levels for individuals of any weight. The INVOS System consists of a portable monitoring system, including technology, which is used with multiple single-use disposable sensors, called SomaSensors or OxyAlert sensors. As of November 30, 2009, the Company had an installed base of 2,927 INVOS System monitors in the United States in 782 hospitals and during the fiscal year ended November 30, 2009, the Company sold 502,026 sensors worldwide. In November 2008, the Company acquired ICU Data Systems, Inc. 

Message Board Search for SMTS: http://www.boardcentral.com/boards/SMTS

In the report, the analyst notes:

"First-quarter income before income taxes was $3.1 million, compared to $2.1 million for the first quarter of 2009.  Net income was $2.0 million, or $0.16 per diluted share, compared with net income of $1.3 million, or $0.10 per diluted share, in the first quarter of 2009.  

"Covidien plc and SMTS recently announced that they have signed a definitive merger agreement under which Covidien will acquire all of the outstanding shares of SMTS for $25.00 per share in cash, for a total of $250 million, net of cash acquired."

SOURCE MicroStockProfit.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
High magnesium levels drive higher mortality in sepsis patients